Inhibition of Mammary Tumor Growth Using Lysyl Oxidase-Targeting Nanoparticles to Modify Extracellular Matrix
Nano Letters2012Vol. 12(6), pp. 3213–3217
Citations Over TimeTop 10% of 2012 papers
Mathumai Kanapathipillai, Akiko Mammoto, Tadanori Mammoto, Joo H. Kang, Elisabeth Jiang, Kaustabh Ghosh, Netanel Korin, Ashley D. Gibbs, Robert Mannix, Donald E. Ingber
Abstract
A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (∼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.
Related Papers
- → Inhibition of Lysyl Oxidase and Lysyl Oxidase-Like Enzymes Has Tumour-Promoting and Tumour-Suppressing Roles in Experimental Prostate Cancer(2016)65 cited
- → Regulation of elastin promoter by lysyl oxidase and growth factors: Cross control of lysyl oxidase on TGF-β1 effects(2007)64 cited
- → Lysyl oxidase: a family of multifunctional proteins(2000)2 cited
- → The role of Lysyl oxidase in epithelial ovarian cancer(2012)
- → Lysyl oxidase protein-lysine 6-oxidase(1998)